COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea (ADVENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00547898
Recruitment Status : Completed
First Posted : October 23, 2007
Last Update Posted : December 23, 2011
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:
This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. This study will compare an investigational new drug (crofelemer) to placebo for the control of HIV-associated diarrhea. The first stage of the study will determine the optimal dose of study drug based on safety and response to therapy and the second stage will evaluate further the effectiveness of the optimal dose.

Condition or disease Intervention/treatment Phase
HIV Associated Diarrhea Drug: Crofelemer 125 mg Drug: Crofelemer 250 mg Drug: Crofelemer 500 mg Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea
Study Start Date : October 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea HIV/AIDS
Drug Information available for: Crofelemer

Arm Intervention/treatment
Experimental: Placebo Drug: Placebo

Experimental: Crofelemer 125 mg Drug: Crofelemer 125 mg
Crofelemer 125 mg

Experimental: Crofelemer 250 mg Drug: Crofelemer 250 mg
Crofelemer 250 mg

Experimental: Crofelemer 500 mg Drug: Crofelemer 500 mg
Crofelemer 500 mg

Primary Outcome Measures :
  1. The primary objective is to determine the proportion of HIV-positive subjects experiencing relief of diarrhea with crofelemer compared to placebo during the placebo-controlled treatment phase. [ Time Frame: 31 days ]
  2. Primary efficacy outcome is two or less watery bowel movements per week during at least two weeks of the treatment phase. [ Time Frame: 31 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of HIV-1 infection confirmed by standard serological tests
  • Stable medical regimen for treatment of HIV disease and associated conditions for at least 4 weeks prior to screening
  • Patient-reported history of diarrhea, defined as either persistently loose stools despite regular ADM use, or one or more watery bowel movements per day without regular ADM use, of at least 1 month duration
  • Colonoscopy within the past 5 years if ≥ 50 years of age.

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Current or past gastrointestinal (GI) medical or surgical conditions
  • Use of certain opiate pain medication within 2 weeks of screening
  • Use of an antibiotic within 2 weeks prior to screening, with the exception of stable antibiotic therapy for prophylactic treatment of infection or an HIV-associated condition
  • CD4 counts < 100 cells/mm3
  • Previous randomization into this study, or into any other crofelemer study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00547898

Show Show 83 study locations
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc. Identifier: NCT00547898    
Other Study ID Numbers: NP303-101
First Posted: October 23, 2007    Key Record Dates
Last Update Posted: December 23, 2011
Last Verified: December 2011
Keywords provided by Bausch Health Americas, Inc.:
HIV Associated Diarrhea
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms